{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:47:16Z","timestamp":1778917636139,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ctrv.2015.10.006","type":"journal-article","created":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T00:48:16Z","timestamp":1446511696000},"page":"853-858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma"],"prefix":"10.1016","volume":"41","author":[{"given":"Giovanni Luca","family":"Ceresoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo Andrea","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"716\u201324","key":"10.1016\/j.ctrv.2015.10.006_b0005","article-title":"Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008","volume":"89","author":"Delgermaa","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.ctrv.2015.10.006_b0010","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1586\/era.09.2","article-title":"Future developments in the management of malignant pleural mesothelioma","volume":"9","author":"Zucali","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2015.10.006_b0015","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0020","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0025","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2003.06.122","article-title":"Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma","volume":"21","author":"Scagliotti","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0030","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0035","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdm501","article-title":"Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)","volume":"19","author":"Castagneto","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0040","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carbolatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ctrv.2009.09.003","article-title":"Second-line treatment for malignant pleural mesothelioma","volume":"36","author":"Ceresoli","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2015.10.006_b0050","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/ijc.26229","article-title":"Pleural malignant mesothelioma epidemic: incidence, modalities of asbestos exposure and occupations involved from the Italian National Register","volume":"130","author":"Marinaccio","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2015.10.006_b0055","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/bjc.2014.312","article-title":"Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey","volume":"111","author":"Ceresoli","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2015.10.006_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199200444-00002","article-title":"Preclinical and clinical pharmacology of vinca alkaloids","volume":"44","author":"Zhou","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2015.10.006_b0065","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0959-8049(98)00416-X","article-title":"Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts","volume":"35","author":"Hill","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2015.10.006_b0070","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.2000.18.23.3912","article-title":"Phase II study of vinorelbine in patients with malignant pleural mesothelioma","volume":"18","author":"Steele","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0075","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/bjc.1990.434","article-title":"Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist","volume":"62","author":"de Haes","year":"1990","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2015.10.006_b0080","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"Muers","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2015.10.006_b0085","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1023\/A:1008236010868","article-title":"Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma","volume":"9","author":"Middleton","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0090","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.bjc.6604421","article-title":"Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma","volume":"99","author":"S\u00f8rensen","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2015.10.006_b0095","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.2008.17.5604","article-title":"Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"27","author":"De Perrot","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0100","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jjco\/hyi127","article-title":"Triplet chemotherapy with cisplatin, gemcitabin and vinorelbina for malignant pleural mesothelioma","volume":"35","author":"Maruyama","year":"2005","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0105","unstructured":"S\u00f8rensen JB, Bech C, S\u00f8rensen P, Frank H. Phase II study of carboplatin and vinorelbine as first line treatment in advanced malignant pleural mesothelioma. Abstract SO6-1. Presented at the 10th International Mesothelioma Interest Group (IMIG) conference, August 31 \u2013 September 2 2010, Kyoto, Japan."},{"key":"10.1016\/j.ctrv.2015.10.006_b0110","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.lungcan.2004.08.005","article-title":"Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma","volume":"47","author":"Fennell","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.10.006_b0115","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1200\/JCO.2007.12.5641","article-title":"Phase II study of vinflunine in malignant pleural mesothelioma","volume":"5","author":"Talbot","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0120","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/annonc\/mdi187","article-title":"Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","volume":"16","author":"Manegold","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0125","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey","volume":"75","author":"Zucali","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.10.006_b0130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.10.006_b0135","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2013.11.011","article-title":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"84","author":"Zucali","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.10.006_b0140","unstructured":"Zauderer MG, Sima CS, Ginsberg MS, Krug LM. Lack of response to vinorelbine in patients with previously treated malignant pleural mesothelioma (MPM): rationale for placebo-controlled trials in the 2nd-line setting. Abstract IB.7. Presented at the 11th International Mesothelioma Interest Group (IMIG) conference, September 11\u201314, 2012, Boston, MA, USA."},{"key":"10.1016\/j.ctrv.2015.10.006_b0145","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.10.006_b0150","first-page":"6","article-title":"Second-line oral vinorelbine following first-line platinum and pemetrexed in malignant pleural mesothelioma","volume":"4","author":"S\u00f8rensen","year":"2012","journal-title":"Eur J Clin Med Oncol (EJCMO)"},{"key":"10.1016\/j.ctrv.2015.10.006_b0155","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.23337","article-title":"Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"112","author":"Zucali","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2015.10.006_b0160","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10147-013-0619-5","article-title":"Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy","volume":"19","author":"Toyokawa","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0165","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0170","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nrd2593","article-title":"Pharmacogenetics in drug discovery and development: a translational perspective","volume":"7","author":"Roses","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctrv.2015.10.006_b0175","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.1999.17.3.1061","article-title":"Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death","volume":"17","author":"Dumontet","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0180","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1038\/sj.onc.1206934","article-title":"Mechanisms of Taxol resistance related to microtubules","volume":"22","author":"Orr","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2015.10.006_b0185","doi-asserted-by":"crossref","first-page":"12436","DOI":"10.1021\/bi0261793","article-title":"Location and properties of the taxol binding center in microtubules: a picosecond laser study with fluorescent taxoids","volume":"41","author":"Lillo","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.ctrv.2015.10.006_b0190","doi-asserted-by":"crossref","first-page":"9356","DOI":"10.1158\/0008-5472.CAN-07-0509","article-title":"Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer","volume":"67","author":"Gan","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.10.006_b0195","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1470-2045(08)70029-9","article-title":"Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?","volume":"9","author":"S\u00e8ve","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0200","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2174\/1381612053764706","article-title":"Improving the targeting of tubulin-binding agents: lessons from drug resistance studies","volume":"11","author":"Verrills","year":"2005","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ctrv.2015.10.006_b0205","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1158\/1078-0432.CCR-05-0285","article-title":"Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy","volume":"11","author":"S\u00e8ve","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.10.006_b0210","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1158\/1535-7163.MCT-05-0244","article-title":"Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel","volume":"4","author":"S\u00e8ve","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2015.10.006_b0215","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-012-1965-0","article-title":"A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma","volume":"70","author":"Zimling","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0220","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/JTO.0b013e318233d6a9","article-title":"Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival","volume":"7","author":"Zimling","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0225","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.1038\/sj.onc.1204712","article-title":"BRCA1 and GADD45 mediated G2\/M cell cycle arrest in response to antimicrotubule agents","volume":"20","author":"Mullan","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2015.10.006_b0230","first-page":"6221","article-title":"BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis","volume":"63","author":"Quinn","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.10.006_b0235","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/sj.bjc.6600859","article-title":"BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells","volume":"88","author":"Tassone","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2015.10.006_b0240","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0140-6736(02)11087-7","article-title":"BRCA1: mechanisms of inactivation and implications for management of patients","volume":"360","author":"Kennedy","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2015.10.006_b0245","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/sj.bjc.6606027","article-title":"Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced\/metastatic non-small-cell lung cancer","volume":"104","author":"Papadaki","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2015.10.006_b0250","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/hmg\/ddh260","article-title":"BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer","volume":"13","author":"Taron","year":"2004","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ctrv.2015.10.006_b0255","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/path.3979","article-title":"BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma","volume":"227","author":"Busacca","year":"2012","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0260","unstructured":"<www.clinicaltrials.gov> (NCT02139904)."},{"key":"10.1016\/j.ctrv.2015.10.006_b0265","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00239-002-2315-3","article-title":"The evolution of the ribonucleotide reductases: much ado about oxygen","volume":"55","author":"Poole","year":"2002","journal-title":"J Mol Evol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0270","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1200\/JCO.2006.06.1101","article-title":"RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer","volume":"24","author":"Bepler","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0275","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/annonc\/mds335","article-title":"Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial","volume":"24","author":"Vilmar","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2015.10.006_b0280","unstructured":"Zimling ZG, Santoni-Rugiu E, Bech C, S\u00f8rensen JB. An unexpected predictive role of RRM1 in malignant pleural mesothelioma treated with cisplatin and vinorelbine. Abstract IA.6. Presented at the 11th International Mesothelioma Interest Group (IMIG) conference, September 11\u201314, 2012, Boston, MA, USA."},{"key":"10.1016\/j.ctrv.2015.10.006_b0285","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1186\/1471-2407-14-709","article-title":"Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions","volume":"14","author":"Szulkin","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2015.10.006_b0290","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.10.006_b0295","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ctrv.2012.11.004","article-title":"Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations","volume":"39","author":"Pinto","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2015.10.006_b0300","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ctrv.2015.10.006_b0305","unstructured":"<www.nccn.org\/professionals\/guidelines\/mpm>."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215001917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215001917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T23:22:55Z","timestamp":1537226575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737215001917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0305737215001917"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.10.006","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}